The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes

Diabetes and Vascular Disease Research

Volumn 12, Issue 2, 2015, Pages 139-145

  Heier, Martin ^a,b,c   Margeirsdottir, Hanna Dis ^b,c,d   Torjesen, Peter Abusdal ^a,b   Seljeflot, Ingebjørg ^a,b   Stensæth, Knut Haakon ^a,b   Gaarder, Mario ^a   Brunborg, Cathrine ^a   Hanssen, Kristian Folkvord ^a,b,c   Dahl Jørgensen, Knut ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Oslo Diabetes Research Centre   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

advanced glycation end products; atherosclerosis; C reactive protein; Diabetes mellitus type 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; METHYLGLYOXAL DERIVED HYDROIMIDAZOLONE 1; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; IMIDAZOLE DERIVATIVE; IMIDAZOLONE;

ADOLESCENT; ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; AGE; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; IMMUNOASSAY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; UPREGULATION; YOUNG MODULUS;

ADOLESCENT; AGE FACTORS; BIOMARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; ELASTIC MODULUS; FEMALE; HUMANS; IMIDAZOLES; IMMUNOASSAY; INFLAMMATION MEDIATORS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; UP-REGULATION; VASCULAR STIFFNESS;

EID: 84923452487     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114560910     Document Type: Article

References (31)

1. Stary HC. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis. 1987 ; 64: 91-108
2. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987 ; 59: 750-755
3. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003 ; 46: 760-765
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 ; 414: 813-820
5. Jandeleit-Dahm KA, Lassila M, Allen TJ. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci. 2005 ; 1043: 759-766
6. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol. 1996 ; 27: 565-573
7. Brouwers O, Niessen PM, Haenen G, et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia. 2010 ; 53: 989-1000
8. Thornalley PJ, Battah S, Ahmed N, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J. 2003 ; 375: 581-592
9. Lund T, Svindland A, Pepaj M, et al. Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans. Diab Vasc Dis Res. 2011 ; 8: 284-294
10. Tardif JC, Heinonen T, Orloff D, et al. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006 ; 113: 2936-2942
11. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005 ; 2: 29-36
12. Reneman RS, Meinders JM, Hoeks AP. Non-invasive ultrasound in arterial wall dynamics in humans: what have we learned and what remains to be solved. Eur Heart J. 2005 ; 26: 960-966
13. Rubin J, Nambi V, Chambless LE, et al. Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities study. Atherosclerosis. 2012 ; 225: 246-251
14. Hu J, Wallensteen M, Gennser G. Increased stiffness of the aorta in children and adolescents with insulin-dependent diabetes mellitus. Ultrasound Med Biol. 1996 ; 22: 537-543
15. Margeirsdottir HD, Stensaeth KH, Larsen JR, et al. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010 ; 33: 2043-2048
16. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003 ; 52: 163-167
17. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009 ; 205: 590-594
18. Thornalley PJ, Hooper NI, Jennings PE, et al. The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract. 1989 ; 7: 115-120
19. Lusis AJ. Atherosclerosis. Nature. 2000 ; 407: 233-241
20. Han Y, Randell E, Vasdev S, et al. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clin Biochem. 2009 ; 42: 562-569
21. Chiarelli F, de Martino M, Mezzetti A, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr. 1999 ; 134: 486-491
22. Sims TJ, Rasmussen LM, Oxlund H, et al. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 1996 ; 39: 946-951
23. Lederer MO, Klaiber RG. Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine cross-links derived from glyoxal and methylglyoxal. Bioorg Med Chem. 1999 ; 7: 2499-2507
24. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999 ; 274: 31740-31749
25. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993 ; 143: 1699-1712
26. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999 ; 97: 889-901
27. Grossin N, Wautier MP, Picot J, et al. Differential effect of plasma or erythrocyte AGE-ligands of RAGE on expression of transcripts for receptor isoforms. Diabetes Metab. 2009 ; 35: 410-417
28. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009 ; 52: 2251-2263
29. McGill HCJ, McMahan CA, Herderick EE, et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000 ; 20: 836-845
30. Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med. 1998 ; 4: 594-601
31. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 ; 27: 2588-2605